Wang Feifei, Maeda Nagamasa, Yasuhara Takao, Kameda Masahiro, Tsuru Emi, Yamashita Tatsuyuki, Shen Yuan, Tsuda Masayuki, Date Isao, Sagara Yusuke
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama 700-8558, Japan.
Acta Med Okayama. 2012;66(6):429-34. doi: 10.18926/AMO/48962.
Human umbilical cord blood (HUCB) cells are rich source of immature stem cells, which have the potential to repair lost tissue. Intractable central nervous system (CNS) disorders are important targets for regenerative medicine, and the application of HUCB cells is being investigated in animal models of CNS disorders. Transplantation of HUCB has induced functional improvements in these animal models due to multiple therapeutic effects including neuroprotection, anti-inflammation, angiogenesis, and neurogenesis. HUCB cells are easily available and safer than other stem cells used in transplantation therapy. In this review, we focus on HUCB transplantation as an encouraging therapeutic approach for animal models of neonatal hypoxic-ischemic brain injury and ischemic stroke.
人脐带血（HUCB）细胞是未成熟干细胞的丰富来源，具有修复受损组织的潜力。难治性中枢神经系统（CNS）疾病是再生医学的重要靶点，目前正在中枢神经系统疾病动物模型中研究HUCB细胞的应用。由于包括神经保护、抗炎、血管生成和神经发生在内的多种治疗作用，HUCB移植已在这些动物模型中诱导了功能改善。HUCB细胞易于获取，且比移植治疗中使用的其他干细胞更安全。在本综述中，我们重点关注HUCB移植，它是一种用于新生儿缺氧缺血性脑损伤和缺血性中风动物模型的令人鼓舞的治疗方法。
